The Beat AML Master Trial found high remission rates and promising safety with triplet therapy in patients with acute myeloid leukemia (AML), according to Ashley Yocum, PhD.
Ashley Yocum, PhD
Advertisement
Articles by Ashley Yocum, PhD
At the 30th European Hematology Association (EHA) Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide.
At the European Hematology Association (EHA) 2025 Congress, Ashley Yocum, PhD, highlights how the Beat AML Master Trial advances safe, personalized treatment and expands targeted therapy options for patients with acute myeloid leukemia (AML).
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Real-World Data Support Dual Benefit of Biologic Therapy for Hidradenitis Suppurativa
2
AI-Driven Research Toolkit Links Aging Biology and Fibrotic Disease
3
Lubiprostone May Offer Renoprotection in CKD
4
Tarlatamab, PD-L1 Inhibitor Combo Shows Promise in 1L Maintenance for ES-SCLC
5
